Dashboard MRSA
Repurposing candidates for MRSA
Methicillin-resistant Staphylococcus aureus
Approved medicines with AI-predicted activity ≥40% against MRSA, leaving out medicines that are already antimicrobials. Each is shown with what it is already used for. They are surfaced computationally for further investigation, not as treatments.
- AI-predicted activity ≥40%
- 860
- Existing antimicrobials set aside
- 117
- Needing review
- 72
- Repurposing candidates
- 671
Repurposing candidates for MRSA
AI prediction · nothing measuredAll 671 repurposing candidates for MRSA.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- EfinaconazoleExisting use: Tinea, Tinea unguium60.5% AI-predicted activityagainst MRSA7 registered studies
- Trametinib Dimethyl SulfoxideExisting use: Cancer, Cutaneous melanoma, Glioblastoma multiforme and 5 more60.4% AI-predicted activityagainst MRSA16 registered studies
- Sorafenib TosylateExisting use: Chromophobe renal cell carcinoma, Clear cell renal carcinoma, Hepatocellular carcinoma and 5 more60.4% AI-predicted activityagainst MRSA50+ registered studies
- PaclitaxelExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 13 more60.2% AI-predicted activityagainst MRSA50+ registered studies
- AcalabrutinibExisting use: Cancer, Chronic lymphocytic leukemia, Mantle cell lymphoma and 1 more60.2% AI-predicted activityagainst MRSA50+ registered studies
- PalbociclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more60.2% AI-predicted activityagainst MRSA50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more60.0% AI-predicted activityagainst MRSA44 registered studies
- Angiotensin Ii AcetateExisting use: Cardiovascular disease, Hypotension, Septic shock and 1 more60.0% AI-predicted activityagainst MRSA10 registered studies
- NilotinibExisting use: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic myelogenous leukemia60.0% AI-predicted activityagainst MRSA50+ registered studies
- SuvorexantExisting use: Insomnia60.0% AI-predicted activityagainst MRSA50+ registered studies
- Leuprolide AcetateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 4 more59.9% AI-predicted activityagainst MRSA50+ registered studies
- Prucalopride SuccinateExisting use: Constipation, Constipation disorder59.7% AI-predicted activityagainst MRSA7 registered studies
- RegorafenibExisting use: Cancer, Colorectal adenocarcinoma, Colorectal cancer and 3 more59.6% AI-predicted activityagainst MRSA50+ registered studies
- Omacetaxine MepesuccinateExisting use: Cancer, Neoplasm59.3% AI-predicted activityagainst MRSA50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more59.3% AI-predicted activityagainst MRSA26 registered studies
- Levocabastine HydrochlorideExisting use: Eye allergy, Nasal congestion59.2% AI-predicted activityagainst MRSA5 registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder59.2% AI-predicted activityagainst MRSANo documented evidence found
- Rocuronium BromideExisting use: Other quaternary ammonium compounds59.1% AI-predicted activityagainst MRSA50+ registered studies
- Ribociclib SuccinateExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 1 more59.1% AI-predicted activityagainst MRSA1 registered study
- FulvestrantExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more59.1% AI-predicted activityagainst MRSA50+ registered studies
- PemigatinibExisting use: Cancer, Cholangiocarcinoma, Neoplasm59.0% AI-predicted activityagainst MRSA50+ registered studies
- DutasterideExisting use: Benign prostatic hyperplasia, Prostate adenocarcinoma, Prostate carcinoma59.0% AI-predicted activityagainst MRSA50+ registered studies
- Vincristine SulfateExisting use: Neoplasm59.0% AI-predicted activityagainst MRSA50+ registered studies
- CabotegravirExisting use: HIV infection, HIV-1 infection, Viral disease58.9% AI-predicted activityagainst MRSA50+ registered studies